Establishment Labs Announces Participation in the UBS Virtual Global Healthcare Conference
NEW YORK, May 11, 2020 (GLOBE NEWSWIRE) -- Establishment Labs Holdings Inc. (NASDAQ: ESTA), a medical technology company focused on women’s health, initially in the breast aesthetics and reconstruction market, today announced that CEO and Founder Juan José Chacón-Quirós and Chief Financial Officer Renee Gaeta, will participate in the UBS Virtual Global Healthcare Conference, which is being held May 18-20, 2020. Mr. Chacón-Quirós and Ms. Gaeta are scheduled to speak to conference attendees at 3:00pm ET on Monday, May 18, 2020.
A live webcast of the presentation will be available to all interested parties on the Establishment Labs investor relations website at . An archived version of the webcast will be available on the same website following the completion of the event.
About Establishment Labs
Establishment Labs Holdings Inc. (NASDAQ: ESTA) is a global medical technology company focused on women’s health, initially in the breast aesthetics and reconstruction market, by designing, developing, manufacturing and marketing an innovative portfolio of silicone gel-filled breast implants, branded as Motiva Implants®, the centerpiece of the MotivaImagine® platform. Motiva Implants® are produced at our two manufacturing sites that are compliant with ISO13485:2016, FDA 21 CFR 820 under the MDSAP program, and are currently commercially available in more than 80 countries through exclusive distributors or the Company’s direct salesforce. In March 2018, Establishment Labs received approval for an investigational device exemption (IDE) from the FDA and initiated the Motiva Implant® clinical trial in the United States in April 2018. In addition to Motiva Implants®, Establishment Labs’ product and technologies portfolio includes the Divina® 3D Simulation System and other products and services. Please visit our website for additional information at .
Investor/Media Contact: David K. Erickson Establishment Labs Holdings Inc. 949-447-6671
